BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 241 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,605,031 | +4.6% | 791,671 | +4.0% | 1.70% | +2.5% |
| Q2 2023 | $5,356,764 | +11.2% | 760,904 | +31.7% | 1.66% | -16.7% |
| Q1 2023 | $4,818,493 | +54.2% | 577,757 | +112.3% | 1.99% | +122.5% |
| Q4 2022 | $3,124,546 | +32.9% | 272,173 | +45.9% | 0.89% | +12.5% |
| Q3 2022 | $2,351,000 | +315.4% | 186,603 | +248.7% | 0.80% | +356.9% |
| Q2 2022 | $566,000 | +187.3% | 53,521 | -47.7% | 0.17% | +112.2% |
| Q1 2022 | $197,000 | -76.0% | 102,425 | -6.9% | 0.08% | -82.8% |
| Q4 2020 | $820,000 | – | 110,000 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |